cyclin D2 Antibody (B-6): sc-376676
- cyclin D2 Antibody (B-6) is a mouse monoclonal IgG2b κ cyclin D2 antibody, cited in 9 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 261-289 at the C-terminus of cyclin D2 of mouse origin
- recommended for detection of cyclin D2 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- m-IgG Fc BP-HRP, m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for cyclin D2 Antibody (B-6) for WB and IHC(P) applications. These reagents are now offered in bundles with cyclin D2 Antibody (B-6) (see ordering information below).
Cyclin D2 Antibody (B-6) is a mouse monoclonal IgG2b kappa light chain antibody engineered to detect cyclin D2, a critical regulator of the cell cycle, across mouse, rat, and human species using applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-cyclin D2 antibody (B-6) targets an epitope located between amino acids 261-289 at the C-terminus of the mouse cyclin D2 protein, ensuring precise recognition and minimal cross-reactivity. Cyclin D2, also called Ccnd2, cD2, Vin1, and Vin-1, plays a pivotal role in controlling the transition from the G1 phase to the S phase of the cell cycle by forming complexes with cyclin-dependent kinases Cdk4 and Cdk6, which phosphorylate the retinoblastoma (Rb) protein. This phosphorylation releases E2F transcription factors, thereby promoting the expression of genes essential for DNA synthesis and cell proliferation. Additionally, cyclin D2 interacts with regulatory proteins such as p21 and p27, which are cyclin-dependent kinase inhibitors that modulate the activity of cyclin D2-Cdk complexes, ensuring proper cell cycle progression and preventing uncontrolled cell division. These interactions are crucial for maintaining normal cellular function and their dysregulation is often implicated in oncogenesis, making cyclin D2 a significant target for cancer research and therapeutic development. Anti-cyclin D2 antibody (B-6) is available in both non-conjugated form and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing researchers with versatile options for diverse experimental needs. Cyclin D2 monoclonal antibody (B-6) supports advanced studies in cell cycle regulation, cancer biology, and the development of targeted therapies aimed at disrupting aberrant cell proliferation pathways.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
cyclin D2 Antibody (B-6) References:
- Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells. | Santiago, F., et al. 1999. J Virol. 73: 9917-27. PMID: 10559304
- Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. | Mai, S., et al. 1999. Neoplasia. 1: 241-52. PMID: 10935479
- Cyclin D2 expression in familial and sporadic breast cancer. | Fischer, H., et al. 2002. Oncol Rep. 9: 1157-61. PMID: 12375011
- Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells. | Friedrichsen, BN., et al. 2003. Mol Endocrinol. 17: 945-58. PMID: 12586844
- Cyclin D2 and p27 are tissue-specific regulators of tumorigenesis in inhibin alpha knockout mice. | Burns, KH., et al. 2003. Mol Endocrinol. 17: 2053-69. PMID: 12855747
- Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin's and Reed-Sternberg cells. | Bai, M., et al. 2004. Mod Pathol. 17: 1338-45. PMID: 15354186
- Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. | Sakuma, M., et al. 2007. Cancer Sci. 98: 380-6. PMID: 17270028
- Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. | Metcalf, RA., et al. 2010. Mod Pathol. 23: 420-33. PMID: 20062012
- Characterization of the murine cyclin D2 gene: exon/intron organization and promoter activity. | Jun, DY., et al. 1997. Mol Cells. 7: 537-43. PMID: 9339900
- Cyclin D2 interacts with cdk-5 and modulates cellular cdk-5/p35 activity. | Guidato, S., et al. 1998. J Neurochem. 70: 335-40. PMID: 9422379
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
cyclin D2 Antibody (B-6) | sc-376676 | 200 µg/ml | $322.00 | |||
cyclin D2 Antibody (B-6): m-IgG Fc BP-HRP Bundle | sc-537997 | 200 µg Ab; 10 µg BP | $361.00 | |||
cyclin D2 Antibody (B-6): m-IgGκ BP-HRP Bundle | sc-535503 | 200 µg Ab; 40 µg BP | $361.00 | |||
cyclin D2 Antibody (B-6): m-IgG2b BP-HRP Bundle | sc-549910 | 200 µg Ab; 10 µg BP | $361.00 | |||
cyclin D2 (B-6) Neutralizing Peptide | sc-376676 P | 100 µg/0.5 ml | $69.00 |